Stage IIIB Breast Cancer Recruiting Phase 2 Trials for Pertuzumab (DB06366)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02827877Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast CancerTreatment
NCT01730833Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast CancerTreatment